SR
This clinical-stage biotech company develops non-opioid, non-liver toxic molecules that activate pain signaling pathways in the midbrain's periaqueductal grey region. Their lead candidate, SRP-001, targets pain-related genes through endocannabinoid and fatty acid amide hydrolase pathways, providing a safer alternative to traditional pain medications.
Updated 18 months ago
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NI
Funding rounds are not available yet.
Founders
Product
Features
- This clinical-stage biotech company develops non-opioid, non-liver toxic molecules that activate pain signaling pathways in the midbrain's periaqueductal grey region. Their lead candidate, SRP-001, targets pain-related genes through endocannabinoid and fatty acid amide hydrolase pathways, providing a safer alternative to traditional pain medications.